Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$20.00
$27.88
$18.70
▼
$94.90
$1.40B-1.12995,078 shs1.35 million shs
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$31.39
-0.1%
$30.62
$28.34
▼
$37.15
$57.44M0.4721,742 shs3,456 shs
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$26.14
$25.32
$23.40
▼
$27.94
$5.23M0.391,750 shs745 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
0.00%-1.72%-5.12%-62.80%-45.68%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
0.00%+1.67%+7.32%-4.94%-1.60%
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
0.00%+0.85%+6.69%-0.31%+4.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$20.00
$27.88
$18.70
▼
$94.90
$1.40B-1.12995,078 shs1.35 million shs
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$31.39
-0.1%
$30.62
$28.34
▼
$37.15
$57.44M0.4721,742 shs3,456 shs
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$26.14
$25.32
$23.40
▼
$27.94
$5.23M0.391,750 shs745 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
0.00%-1.72%-5.12%-62.80%-45.68%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
0.00%+1.67%+7.32%-4.94%-1.60%
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
0.00%+0.85%+6.69%-0.31%+4.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.93
Moderate Buy$110.91454.55% Upside
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
2.51
Moderate Buy$31.39N/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
2.58
Moderate Buy$26.14N/A

Current Analyst Ratings Breakdown

Latest OZEM, THNR, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Reiterated RatingBuy
11/4/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
10/23/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
10/6/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
9/18/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
9/9/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Reiterated RatingBuy
9/9/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Reiterated RatingMarket Outperform$110.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$24.99 per shareN/A
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/AN/AN/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$141.20M-$1.29N/AN/AN/AN/A-29.18%-27.62%N/A
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/A21.90N/AN/AN/AN/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/A22.59N/AN/AN/AN/AN/AN/A

Latest OZEM, THNR, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.51-$0.66-$0.15-$0.66$50.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$0.050.16%N/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$0.220.84%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
11.90
11.91
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
28170.03 million66.18 millionOptionable
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/A1.83 millionN/AOptionable
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A200,000N/AN/A

Recent News About These Companies

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher
What the Holidays Hold for GLP-1 Stocks in THNR
NTHM's Index Rebalance Puts Thematic Rotation to Work
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$20.00 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$19.75 -0.25 (-1.25%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Roundhill GLP-1 & Weight Loss ETF stock logo

Roundhill GLP-1 & Weight Loss ETF NASDAQ:OZEM

$31.39 -0.03 (-0.10%)
Closing price 11/13/2026 03:57 PM Eastern
Extended Trading
$31.12 -0.27 (-0.86%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management. OZEM was launched on May 21, 2024 and is issued by Roundhill.

Amplify Weight Loss Drug & Treatment ETF stock logo

Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR

$26.14 0.00 (0.00%)
Closing price 11/13/2026 04:10 PM Eastern
Extended Trading
$26.12 -0.02 (-0.08%)
As of 11/13/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.